MicroRNAs: New Players in the Pathobiology of Preeclampsia

Kelsey R. Bounds1, Valorie L. Chiasson1, Lu J. Pan1, Sudhiranjan Gupta2 and Piyali Chatterjee1*

1Department of Internal Medicine, Baylor Scott & White Health, Texas A&M Health Science Center, Temple, TX, United States, 2Department of Medical Physiology, Baylor Scott & White Health, Texas A&M Health Science Center, Temple, TX, United States

Our understanding of how microRNAs (miRNAs) regulate gene networks and affect different molecular pathways leading to various human pathologies has significantly improved over the years. In contrary, the role of miRNAs in pregnancy-related hypertensive disorders such as preeclampsia (PE) is only beginning to emerge. Recent papers highlight that adverse pregnancy outcomes are associated with aberrant expression of several miRNAs. Presently, efforts are underway to determine the biologic function of these placental miRNAs which can shed light on their contribution to these pregnancy-related disease conditions. The discovery that miRNAs are stable in circulation coupled with the fact that the placenta is capable of releasing them to the circulation in exosomes generates a lot of enthusiasm to use them as biomarkers. In this review, we will summarize the recent findings of our understanding of miRNA regulation in relation to PE, a hypertensive disorder of pregnancy. Particular emphasis will be given to the role of key miRNA molecules such as miR-210 and miR-155 that are known to be consistently dysregulated in women with PE.

Keywords: pregnancy, microRNAs, preeclampsia, angiogenesis, inflammation

INTRODUCTION

Preeclampsia (PE) is a multisystem pregnancy disorder that affects about 10 million women globally (1). PE is known to significantly contribute to maternal and perinatal morbidity and mortality. Each year approximately 76,000 maternal deaths and 500,000 babies die due to hypertensive disorders of pregnancy (2). PE is diagnosed by de novo onset of hypertension (≥140 mmHg systolic blood pressure or ≥90 mmHg diastolic blood pressure) at or after midgestation and presence of any one of these symptoms such as proteinuria, thrombocytopenia, renal insufficiency, cerebral, or visual disturbances (3). Because proteinuria does not always correlate with outcomes, it is no longer considered a clinical diagnostic feature of PE (4). The incidence of PE is steadily rising due to additional risk factors that include advanced maternal age, obesity, diabetes, etc. (5). Recent pieces of evidence predict long-term risk of cardiovascular diseases such as stroke, pulmonary hypertension, and metabolic or endocrine problems in both the mother and the child (6). PE can lead to more severe complications such as Hemolysis Elevated Liver enzymes and Low Platelet count (HELLP) syndrome or eclampsia with seizures and visual disturbances. Currently, the only curative therapy of PE is delivery of the baby and the placenta.

The exact underlying causes of PE still remain elusive. PE is thought to occur as a consequence of several factors, including defective spiral artery remodeling, placental oxidative stress, endothelial...
dysfunction, and systemic inflammation. In normal pregnancies, cytotrophoblasts (CTBs) migrate through the decidua and myometrium in order to invade the maternal spiral arteries of the endothelium and tunica media which supply blood to the developing fetus. This causes the arteries to become large vessels with low resistance facilitating sufficient blood flow to the placenta.

In the first stage of PE, the CTBs fail to penetrate the myometrium creating narrow vessels resulting in placental hypoperfusion leading to abnormal remodeling of the spiral arteries (7). The second stage of the disease occurs due to failure of spiral artery remodeling and hypoperfusion leading to placental hypoxia, oxidative stress, endoplasmic reticulum (ER) stress, and subsequent release of several placental factors into the maternal circulation (3). The release of these factors and their interaction with the maternal vasculature results in endothelial dysfunction, a typical characteristic of PE. In addition, these factors also contribute to excessive systemic inflammation and an imbalance of the immune system that causes clinical manifestations of PE.

Regardless of the initiating causes, the placenta is known to play a pivotal role in the initiation and progression of PE. Removal of the placenta causes cessation of clinical symptoms of PE. Therefore, it is important to understand how the gene regulatory networks are controlled within the placenta during PE. In recent years, microRNAs (miRNAs) have garnered much attention as they have emerged as a new class of gene expression regulators. In this review, we will discuss our current understanding of the role of the most consistently dysregulated miRNAs, miR-210 and miR-155 in PE.

**miRNAs AND THEIR BIOGENESIS**

MicroRNAs are small (~22–25 nt), endogenous, single-stranded, non-coding RNAs that regulate gene expression preferentially by binding to the untranslated region (3′ UTR) of a target gene (8). These regulatory molecules play an important role in the post-transcriptional regulation of gene expression by causing translational inhibition or mRNA cleavage thereby silencing gene expression unlike protein-coding genes (9). There are about 2,500 miRNAs and 1,000 of these are validated in humans alone (10). One miRNA can bind to multiple targets and result in the translational suppression of numerous genes. miRNAs are involved in several critical processes such as development, cell differentiation, and migration to name a few. Not surprisingly miRNAs also contribute to the conception and maintenance of pregnancy (11) by regulating key processes such as inflammation (12), immune tolerance (13), angiogenesis (14), and apoptosis (15). Aberrant expression of miRNAs is found in several pregnancy-related disorders such as PE, intrauterine growth restriction, and preterm birth.

The miRNA biogenesis occurs via multistep process and is regulated by a set of proteins and enzymes at various steps such as transcription, processing steps, or miRNA turnover. miRNAs are first transcribed as long primary transcripts by RNA pol II. miRNA sequences are located within the hairpin structure of the primary transcript. In animals, the nuclear RNase III enzyme, Drosha, cuts the primary miRNA (pri-miRNA) leaving behind about 70 nt hairpin sequence called the precursor miRNA or (pre-miRNA) within the nucleus. Then, exportin-5 exports the pre-miRNA out of the nucleus to be cleaved by Dicer-1, a cytoplasmic RNase III enzyme. This forms a 22-nt-long double-stranded duplex. This duplex then associates with an Argonaute family protein (the core of the RNA-induced silencing complex or RISC). The arm of the duplex that is incorporated into the RISC mediates association with target mRNAs by complementary base pairing. Both strands of the mature miRNA have a potential to bind and regulate their targets, but one strand usually accumulates at significantly higher levels which is the functionally dominant miRNA and the minor product is often preferentially degraded.

GW182 then interacts with Ago proteins and promote translational inhibition and mRNA degradation (9, 16). GW182 can act as a scaffold to interact with poly A binding protein (PABP) and competes for binding to PABP with eukaryotic initiation factor 4 G. Due to this interaction, miRNAs are not circularized and this leads to the decrease in translation efficiency. The resulting miRNAs are subsequently targeted for rapid degradation by deadenylase complex (16). This is followed by decapping of the mRNA and makes it prone to exonucleolytic cleavage. The cellular concentration of a miRNA is expected to correlate with its repressive activity. A highly expressed miRNA is thought to repress the translation of its target more and, therefore, be more functionally important than that of an under expressed miRNA. This is supported by several observations of overexpression of miRNAs leading to dose-dependent decreases in the levels of the target mRNAs (17–19).

In addition to this canonical pathway, there have been other miRNA pathways recently discovered (Figure 1). Mirtrons, an atypical miRNA, is produced from short hairpin introns that are released by the splicing machinery. Then, they are linearized by the lariat debranching enzyme and further folded into pre-miRNA. Mirtrons bypass Drosophila cleavage unlike the canonical pathway. However, they get processed further in a comparable manner (20). Another pathway that has been recently discovered shows direct cleavage of pre-miRNA by Ago2 not Dicer as in the traditional canonical pathway (21). The function of these miRNAs during pregnancy and pregnancy-related disease conditions are currently unknown.

The importance of miRNA biogenesis machinery is highlighted by the observation that the lack of even a single protein in this pathway causes profound defects in different reproductive organs. Drosha (a nuclear RNase III enzyme) is responsible for cleaving pri-miRNAs to pre-miRNAs. If Drosha is specifically knocked down in spermatogenic cells in postnatal testes using Cre-Lox, spermatogenesis is disrupted (22). The role of another protein DGC8R8 involved in the miRNA biogenesis pathway that interacts with Drosha to produce pre-miRNA in the nucleus is determined using a conditional knockout mouse model. Kim et al. demonstrated that a Dgc8 conditional knockout mouse produced using a progesterone receptor (PR)-Cre was required for uterine development and fertility (23). In addition, DGC8R8-dependent miRNAs are required for immune modulation, reproductive cycle, and steroid hormone responsiveness. Loss of Dicer (a cytoplasmic RNase III enzyme) leads to embryonic lethality and is essential for maintaining the stem cell population during early mouse development (24). All the key molecules of the
FiGURe 1 | MicroRNA (miRNA) biogenesis pathways: in the canonical pathway, miRNAs are first transcribed by RNA polymerase II in the nucleus that generates a primary miRNA (pri-miRNA), which are then processed by the Drosha–DGCR8 complex to produce precursor miRNAs (pre-miRNAs). Pre-miRNAs are then transported via exportin 5 into the cytoplasm, and are processed by Dicer-TRBP and loaded into AGO2-RISCs to downregulate target gene expression. GW182 (shown here) binds to PABP and prevents circularization of mRNA and promotes rapid degradation. miRNAs are also produced through non-canonical pathways (shown in the right), such as spliceosome-dependent mechanisms, without Drosha cleavage as shown here.
miRNA biogenesis pathway have also been found to be expressed in the placenta (25). Ago2 has been shown to be essential for early stages of mouse embryogenesis (26). A mutation in Ago2 in mouse cause defects in placentual development and embryonic death at midgestation (27). Whether other miRNA biogenesis proteins also play a critical role in placentual development remains unanswered. This is largely due to the fact that a mouse deficient in any of the miRNA biogenesis proteins often exhibit early developmental defects prior to placentation formation.

PLACENTAL miRNAs AND THEIR FUNCTION

MicroRNAs are abundantly expressed in the placenta during pregnancy and a study by Liang et al. demonstrated the placental miRNA profiles (28). A major source of placental miRNAs is the villous trophoblasts (29, 30). Mammalian placental miRNAs emerged late during evolution. The placenta expresses miRNAs at different stages of pregnancy, including some that are expressed in a spatio-temporal manner. This suggests that miRNAs play a role in controlling genes and are also modulated by several additional factors such as environment, signaling, and epigenetic pathways.

Interestingly, some novel miRNAs are specifically expressed in the placenta (31). These placenta-specific miRNAs are largely clustered in three groups such as chromosome 14 miRNA cluster (C14MC), C19MC, and miR-371-373 cluster. A large part of trophoblastic miRNAs (trophomiRs) are expressed from a gene cluster C14MC spanning about 40 kb containing 52 miRNAs and is derived exclusively from maternally imprinted genes. The cluster is highly expressed at the first trimester and gradually less expressed in the third trimester. The cluster is mostly expressed in the embryonic and the placental tissues and is known to be involved in regulation of cellular differentiation and fate (31).

Another gene cluster found on chromosome 19, C19MC spans about 100 kb of genomic DNA and harbors 46 intronic miRNA genes that express 58 miRNA species (32). The miRNAs from this one cluster is the most abundant in trophoblasts in the human placenta. For C19MC miRNAs paternally inherited allele is only expressed in the placenta. Within the placenta, the C19MC miRNAs are expressed as early as week 5 of pregnancy and the expression increases as pregnancy advances. Hromadnikova et al. reported an upregulation of circulating C19MC miRNAs (miR-516-5p, miR-517*, miR-520a*, miR-525, and miR526a) in patients with PE (33). Recent findings by Delorme-Axford et al. suggest that high levels of expression of C19MC cluster in primary human trophoblast confer resistance to infection by viruses (34). These miRNAs function by inducing autophagy in placental cells. Interestingly, overexpression of C19MC cluster also confers viral resistance to non-placental cells which strongly indicates that this cluster is important to attenuate invading viral pathogens.

miR-371-373 cluster is a small miRNA cluster in humans and a homologous cluster miR-290-295 is also found in mice. Interestingly, miR-371 cluster is also found on chromosome 19 within 1,050 bp region adjacent to the C19MC cluster. This cluster is highly expressed in the primary trophoblast cells and increased in the third trimester. The cluster is also expressed in early embryonic primordial germ line, the germ line stem cell component of adult testis and stem cell lines from early mouse lineages. A detailed review of how these robustly expressed placenta-specific miRNAs are involved in pregnancy complications can be found in the publications by Morales-Prieto et al. (31) and Mouillet et al. (35).

Given that miRNAs play an important role in several processes, an aberrant placental expression of miRNAs would correlate with several pathological diseases including PE. Recent experimental data suggests that angiogenesis, trophoblast proliferation, and immune tolerance which are key processes in PE are governed by miRNAs. Angiogenesis is known to play a pivotal role in PE pathogenesis and several miRNAs (angiomiRs) are known to alter angiogenic pathways. miR-16 and miR-29 are vascular endothelial growth factor (VEGF)-A and the reduction in VEGF-A subsequently inhibits migration of human umbilical vein endothelial cells (HUVECs) (36–38). miR-494 arrests the transition of growth and synthesis phase (G1/S transition) by targeting cyclin-dependant kinase 1 (CDK1) and cyclin D1 (CCND1) (39). The supernatant from miR-494 overexpressing dMSCs impairs HUVEC capillary formation by suppressing VEGF. Furthermore, miR-17, miR-20a, and miR-20b overexpression causes defective cytotoxic trophoblast migration and spiral artery remodeling by targeting Ephrin B2 and Ephrin B4 (40). miR-125b-1-3p, miR-328, and miR-21 are also implicated as angiomiRs. Other angiomiRs such as miR-210 and miR-155 will be discussed in detail later in this review.

Failure of trophoblast invasion leads to defects in spiral artery remodeling, a hallmark of PE pregnancies. Several miRNAs, including miR-16, miR-29b, miR-34a, miR-155, miR-210, and miR-675, decrease proliferation and migration of trophoblasts. Low expression of miR-34a in PE is associated with an increase in SERPINA3 that is involved in trophoblast invasion (41). In contrary, miR-377a-5p, miR-376c, and miR-21 have been shown to enhance trophoblast proliferation and invasion via modulating the nodal signaling pathway (42–44). Another well-studied cluster is the miR-17-92 cluster that can regulate the differentiation of primary human trophoblasts (45). However, the deletion of miR-17-92 cluster in vivo in mouse gives rise to smaller pups that eventually die at birth (46).

During normal pregnancy, a tolerogenic immune environment is regulated by several immune-regulatory miRNAs. miR-17-92 cluster, miR-146a, miR-155, and miR-223 are known to be dysregulated in PE and associated with many immune cells such as macrophages, dendritic cells, and Tregs function (47). miR-126 also modulates innate immune responses in plasmacytid DCs (48). Interestingly, high expression of TGFβ3 stimulates miR-494 in decidual mesenchymal stem cells (dMSCs) which in turn inhibits M2 macrophage polarization by reducing PGE2 production (49). miR-181a was found to be upregulated in MSCs of severe PE compared to normal patients and blocks TGFβ pathways (50). HLA-G is known to be involved in developing immune tolerance in pregnancy and miR-152 has been shown to repress HLA-G expression in JEG-3 choriocarcinoma cells. Furthermore, miR-152 plays a role as an immune response enhancer by increasing NK cell-mediated cytolyis (51). miR-152 expression has been found to be higher and conversely, HLA-G expression to be lower.
miR-210 has been shown to be overexpressed in preeclamptic pregnancies. It has been reported that multiple miRNAs are upregulated or downregulated in placentas of women with PE compared to normal pregnant women. In particular, one miRNA, miR-210, has been shown to be overexpressed in preeclamptic placentas by several independent groups (52, 53). First, Pineles et al. screened 157 miRNAs using qRT-PCR and demonstrated that miR-210 is upregulated in PE placentas. Several subsequent studies by Zhu et al., Mayor-Lynn et al., and Enquobahrie et al., further confirmed increased expression of miR-210 in the placentas of PE women (53–55). miR-210 is an intronic miRNA located within genetic loci of transcript AK123483. Transcription factors that regulate the miR-210 expression include hypoxia-inducible factors (HIF-1α, HIF-2α), and NF-κB (56). While it has been reported that placental miR-210 expression is upregulated in PE patients there are few targets of miR-210 that have been identified in the etiology of PE. A few studies to date are described as follows. miR-210 has been strongly linked with hypoxia that leads to insufficient trophoblast invasion and abnormal spiral artery remodeling contributing to PE (57) and is upregulated by (HIF-1α) which binds to HIF responsive element on the proximal promoter 400 bp upstream (58). By overexpressing miR-210, HIFs control the response to hypoxia on a cellular level by regulating genes involved in different processes such as angiogenesis, erythropoiesis, cell proliferation, differentiation, apoptosis, inflammation, and metabolism.

Zhang and colleagues demonstrated that miR-210 expression is increased in placentas of PE patients and is also rapidly induced by hypoxia in trophoblast cell lines (57). This group found that miR-210 is not only regulated by HIF-1α but also by NF-κB p50. Both ephrin-A3 (EFNA3) and homeobox-A9 (HOXA9) are known for different biological functions such as cell migration and vascular remodeling and development during embryogenesis are direct targets of miR-210. EFNA3 expression is suppressed solely by translational repression, but HOXA9 expression is suppressed by both mRNA degradation and translational repression. The group also found that both targets were downregulated in placentas with PE compared to placentas from control patients. Ectopic expression of miR-210 in trophoblast cells attenuated cell migration and invasion.

One study hypothesized that overexpression of miR-210 would cause mitochondrial dysfunction in PE. When mitochondria are dysfunctional they produce excessive amounts of reactive oxygen species (ROS) which could be a trigger of PE. During normal pregnancies, there is a state of oxidative stress and this is only heightened during pregnancies plagued by PE. ROS, along with estrogen and some inflammatory cytokines, are involved in stabilizing HIF-1α during normoxia. Muralimanoharan et al. found mitochondrial dysfunction in placentas with PE which was associated with elevated ROS production and HIF-1 stabilization. They also found an upregulation of miR-210 and downregulation of ISCU (iron–sulfur cluster scaffold homolog) in PE placentas (59). Their data suggest that the upregulation of miR-210 represses mitochondrial function via mitochondria-associated ISCU. Another group evaluated the association between miR-210 and ISCU (60). They found an inverse correlation—when there was an overexpression of miR-210 in their trophoblast cell lines there was a decrease in ISCU. Lee et al. also showed an increase in iron deposition in Swan-71 trophoblasts after hypoxia was induced. They also found an accumulation of intracellular iron and decreased matrigel invasion after inhibiting ISCU through transfection of the Swan-71 trophoblasts which suggests that downregulation of ISCU by miR-210 could inhibit trophoblast invasion, a common precursor to PE. This study is yet another pathological finding that connects miR-210 and PE.

Another study using a high throughput screening (HTS)-based miRNA profiling of human placentas demonstrated miR-210 to be increased in PE patients. A steroidogenic enzyme, hydroxysteroid (17β) dehydrogenase 1 that is expressed mainly in the syncytiotrophoblasts of chorionic villi of the placenta is a direct target of miR-210. Importantly, plasma levels of hydroxysteroid (17β)-dehydrogenase are mostly reduced prior to onset of PE raising the possibility of using it as a biomarker (61). Potassium channel modulatory factor 1 (KCMF1) was predicted to be a target of miR-210 using target prediction algorithms. Although other studies indicated that KCMF1 is involved in proliferation, migration, and invasion in epithelial cancers; however, its role in the placenta is unknown. Luo et al. first demonstrated that the levels of KCMF1 were significantly lower in placentas of PE patients and inversely correlate with miR-210 expression (62). KCMF1 is experimentally validated as a direct target of miR-210 using dual luciferase assay in HTR8/SVneo cells. In addition, the inflammatory factor tumor necrosis factor-α (TNF-α) could upregulate miR-210 expression while suppressing KCMF1 levels. Therefore, miR-210 expression may contribute to the occurrence of PE by interfering with KCMF1-mediated signaling in the human placenta.

The role of miR-210 in angiogenesis, iron metabolism, and trophoblast invasion is well established but the role of miR-210 in the regulation of genes related to immune responses is only beginning to emerge. We reported that activation of toll-like receptor 3 (TLR3) via poly I:C (a synthetic double-stranded RNA viral mimic) produces the PE-like symptoms of hypertension, endothelial dysfunction, and proteinuria in mice only when pregnant. We demonstrated that both HIF-1α and NF-κB p50 bind the miR-210 promoter and induce its expression, were also significantly upregulated in poly I:C treated mouse placentas. Poly I:C treatment of human CTBs significantly increased HIF-1α, NF-κB p50, and miR-210 levels. In addition, we demonstrate that miR-210 directly targets signal transducer and activator of transcription 6 (STAT6) resulting in decreases of IL-4 production which causes the balance of pro to anti-inflammatory cytokine production in favor of pro-inflammatory cytokines. These findings demonstrate that in a TLR3-induced preeclamptic mouse model, placental miR-210 expression is induced via HIF-1α and
Another miRNA that is linked to PE is miR-155 (64–66). It is involved in various functions that affect different pathways during PE, such as mitochondrial dysfunction, angiogenesis, and immune system.

THE ROLE OF miR-155 IN PE

Another miRNA that is linked to PE is miR-155 (64–66). It is processed in humans from exon 3 of the non-protein coding B-cell integration cluster (BIC) RNA (67). Its expression is induced in activated B-cells, T-cells, and macrophages and several studies have found it overexpressed in several types of B-cell lymphoma (24).

Zhang et al. reported that overexpression of miR-155 contributes to PE by downregulating cysteine-rich protein 61 (CYR61), an important angiogenic regulating factor during pregnancy (68). A targeted knockout of the CYR61 gene in mice resulted in embryonic death due to placental vascular insufficiency and compromised vessel integrity (69). It has been shown in previous studies that CYR61 gene was significantly decreased in human placentas with PE (70). CYR61 is known to induce the expression of VEGF and this group hypothesized that a decrease in CYR61 would cause a decrease in VEGF in placentas with PE. miR-155 targeted a region within the 3'UTR sequence of the CYR61 gene which leads to decreased levels of CYR61 in PE placentas. These findings propose a miR-155-CYR61-VEGF pathway where an overexpression of miR-155 causes a downregulation of CYR61 which leads to decreased levels of VEGF, therefore, reducing placental angiogenesis.

Liu et al. demonstrated that the placental expression of miR-155 increased and vascular endothelial growth factor (VEGF) decreased in a rat model of PE induced by l-nitroarginine methyl ester (l-NAME) (71). Since VEGF plays an important role in the vascular lumen formation during angiogenesis it seems to be a key player in pregnancy. A decrease in VEGF causes reduced angiogenesis which is linked with PE because of improper placental vascular network formation and function such as shallow invasion of trophoblast cells causing placental ischemia. This group also found that the upregulation of miR-155 inversely correlated with a decrease in VEGF levels within the placentas suggesting that miR-155 induces a downregulation of VEGF expression which contributes to the development of PE.

Several researchers have shown miR-155 to attenuate trophoblast proliferation through regulation of cyclin D1 in HTR-8/SVneo extravillous trophoblast cells. It also targets interleukin-1 receptor-associated kinase M (IRAKM), NF-κB inhibitor interacting Ras-like 1 (NKRAS1), and phosphatase and tensin homolog (PTEN). By targeting these regulators, miR-155 enhances AP-1/NF-κB pathway (72). Also, increased expression of miR-155 has been implicated in shallow placental invasion as seen in PE (73).

miR-155 also regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from women with severe PE (74). Angiotensin II (Ang II) could play an important role in the pathogenesis of PE by inducing low-grade inflammation on endothelial cells, vascular cells, smooth muscle cells, and immune cells. miR-155 has been also linked with regulating the expression of renin–angiotensin system factors. In this study, Cheng et al. isolated HUVECs from normal pregnant women and patients with severe PE. Furthermore, significant increases in Ang II and AT1R within the HUVECs and reduced expression of miR-155 from PE patients compared to normal pregnant women indicates an association between them. In addition, the authors demonstrate that miR-155 directly targets AT1R. These data suggest that patients with PE have a decreased expression of miR-155 which leads to an increase in AT1R, thus influencing renin–angiotensin system expression contributing to the development of PE.

O’Connell et al. found that miR-155 is a common target of inflammatory mediators, and since it is known to be an oncogene, their findings potentially identified a link between inflammation and cancer (75). In their study, they found that miR-155 was induced by TLRs in macrophages. This means that miR-155 is a component of the primary macrophage response to different types of inflammatory mediators. miR-155 is known to be upregulated in placenta-associated miRNAs that are dysregulated during PE.

In the future, how these miRNAs contribute to endothelial dysfunction and hypertension during pregnancy leading to PE needs to be addressed (76). Specifically, to delineate the role of the individual miRNAs in PE additional in vivo studies utilizing placenta-specific overexpression or gene knockout models are needed to answer these unanswered questions.

### Table 1

| Function | miRNAs involved | Known targets/pathways |
|----------|-----------------|------------------------|
| Angiogenesis | miR-16, miR-29 | Vascular endothelial growth factor (VEGF-A) |
| | miR-17, miR-20a, miR-20b | CDK6/CYCD1 |
| | miR-125b-1-3p | EPHB2, B4 |
| | miR-155 | S1PR |
| | miR-21 | PTEN, positive regulator of VEGF-A and HIF-1α |
| | miR-210 | EFNA3, HOXA9, HSD17 |
| Trophoblast proliferation | miR-16, miR-29b | Inhibits trophoblast proliferation |
| | miR-34a | SERPINA3 |
| | miR-210 | KCMF-1 |
| | miR-155 | CYCD1 |
| | miR-378a-5p, miR-376c, miR-21 | Promotes trophoblast proliferation by nodal signaling pathway |
| | miR-17-92 cluster | Differentiation of primary trophoblasts |
| Inflammation | miR-146a | Inflammatory pathway |
| | miR-155 | IL-17A pathway |
| | miR-494 | Macrophage proliferation by reducing PGE2 production |
| | miR-181a | TGFβ pathway |
| | miR-152 | HLA-G |
| | miR-210 | STAT6/IL-4 pathway |
CONCLUSION
The discovery of miRNAs expanded our knowledge about how they regulate gene expression by modulating several key cellular processes. Currently, research is underway to use miRNA-based biomarkers as diagnostic tool for various diseases including PE. A large number of studies have been performed using miRNA profiling coupled with validation studies of these miRNAs in blood/serum/plasma of PE patients. In the future, the success of using these miRNAs as biomarkers in PE will greatly rely on the determination of expression of these miRNAs at different stages of pregnancy and how it can alter the power of predicting disease progression as well as clinical outcome. Another diagnostic approach gaining attention is the determination of concentration and miRNA content of exosomes across gestation which may serve as an early marker for PE (78). In addition, elucidating the functional role these dysregulated miRNAs play may identify important pathways involved in PE.

A paucity of data of the role of miRNAs in PE presently limits their use in therapeutics. Few miRNAs involved in other diseases are validated in clinically relevant animal models and are presently in preclinical/clinical trials. Typically, in a disease setting, antagoniRs decrease detrimental miRNAs and in contrast miRNA mimics can increase the abundance of beneficial miRNAs. Clinical trials are now underway for a liver-specific miRNA, miR-122 for treatment of chronic HCV infection followed by studies in mice and non-human primates. The success of administration of anti-miR-122 was mainly due to the ease by which these miRNAs predominantly accumulate in the liver (79). Based on tumor suppressive effects of miR-34, liposome formulated mimic-based drug is also administered currently in patients with primary liver cancer (80). We are in need of appropriate animal disease models and human function studies for future clinical trials using miRNA-based therapeutics.

To facilitate miRNA-based therapeutics in pregnancy-related disorders, future studies with more emphasis on minimizing off target effects, improving timing and dosing to obtain minimal side effects and elucidating the exact uptake mechanism of these miRNAs by other organs are needed. Therefore, increasing our knowledge of the function of miRNAs in pregnancy-related disorders is necessary in order to develop therapeutic strategies in the future.

AUTHOR CONTRIBUTIONS
KB, VC, LP, and SG wrote parts of the manuscript and edited. PC wrote, organized, and finalized the manuscript.

ACKNOWLEDGMENTS
We would like to thank Bryan Moss, medical illustrator, BSWH for his help with the figure. This work was supported by grants from the American Heart Association [14GRNT20490320 to SG and 13SDG14630018 to PC].
abnormalities during uterine development in mice. Sci Rep (2016) 6:20242. doi:10.1038/srep20242

24. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, et al. Dicer is essential for mouse development. Nat Genet (2005) 35(3):215–7. doi:10.1038/ng1253

25. Mouillet JF, Chu T, Sadowsky Y. Expression patterns of placental microRNAs. Birth Defects Res A Clin Mol Teratol (2011) 91(8):737–43. doi:10.1002/bdra.20782

26. Lykke-Andersen K, Gilchrist MJ, Grabarek JB, Das P, Miska E, Zernicka-Goetz M. Maternal Argonaute 2 is essential for early mouse development at the maternal-zygotic transition. Mol Cell Biol (2008) 19(10):4383–92. doi:10.1091/mcb.E08-02-0129

27. Cheulkou S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature (2010) 465(7298):584–9. doi:10.1038/nature09092

28. Liang Y, Rizdzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics (2007) 8:166. doi:10.1186/1471-2164-8-166

29. Morales-Prieto DM, Chaiwanyeng W, Opsina-Prieto S, Schneider U, Herrmann J, Gruhn B, et al. MicroRNA expression profiles of trophoblastic cells. Placenta (2012) 33(9):725–34. doi:10.1016/j.placenta.2012.05.009

30. Donker RB, Mouillet JF, Chu T, Hube L, Stolz DB, Morelli AE, et al. The expression profile of C19MC microRNAs in primary human trophoblast cells and exposure to isoprenaline. Mol Hum Reprod (2012) 18(8):417–24. doi:10.1093/molehr/gat133

31. Morales-Prieto DM, Opsina-Prieto S, Chaiwanyeng W, Schoenelen B, Markert UR. Pregnancy-associated miRNA-clusters. J Reprod Immunol (2013) 97(1):51–61. doi:10.1016/j.jri.2012.11.001

32. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification and functional analysis of the microRNA-miR-17-92 cluster in human testes. Proc Natl Acad Sci U S A (2005) 102(30):10869–74. doi:10.1073/pnas.0500710102

33. Herrmann J, Gruhn B, et al. MicroRNA expression profiles of trophoblastic cells. FEBS Lett (2015) 589(11):1602–13. doi:10.1016/j.febslet.2015.08.018

34. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of microRNAs and miRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor. Reprod Sci (2011) 18(1):46–56. doi:10.1177/1933719110374115

35. Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, Williams MA. Placental microRNA expression in pregnancies complicated by preeclampsia. Am J Obstet Gynecol (2011) 204(2):178.e12–21. doi:10.1016/j.ajog.2010.09.004

36. Chan YC, Banerjee J, Choi SY, Sen CK. miR-210: the master hypoxamir. Microcirculation (2012) 19(9):570–83. doi:10.1111/j.1537-2995.2012.00474.x

37. Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, et al. Elevated levels of microRNA-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm placenta and small-for-gestational-age pregnancies. Am J Pathol (2013) 182(2):567–77. doi:10.1016/j.ajpath.2012.07.002

38. Huang X, Le QT, Giaccia AJ. miR-210 – micromanager of the hypoxia modulatory factor 1. J Cell Mol Med (2009) 13(4):613–26. doi:10.1111/j.1582-4934.2009.00600.x

39. Lee DC, Romero R, Kim JS, Tarca AL, Montenegro D, Pineles BL, et al. miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm placenta and small-for-gestational-age pregnancies. Am J Pathol (2013) 182(2):567–77. doi:10.1016/j.ajpath.2012.07.002

40. Lee DC, Romero R, Kim JS, Tarca AL, Montenegro D, Pineles BL, et al. miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm placenta and small-for-gestational-age pregnancies. Am J Pathol (2013) 182(2):567–77. doi:10.1016/j.ajpath.2012.07.002
63. Kopriva SE, Chiasson VL, Mitchell BM, Chatterjee P. TLR3-induced placental miR-210 down-regulates the STAT6/interleukin-4 pathway. *PLoS One* (2013) 8(7):e67760. doi:10.1371/journal.pone.0067760

64. Lazar L, Rigo J. PP088. The role of microRNA in pathogenesis of pre-eclampsia-miRNA network analysis. *Pregnancy Hypertens* (2013) 3(2):99.

65. Murphy MS, Casselman RC, Tayade C, Smith GN. Differential expression of plasma microRNA in preeclamptic patients at delivery and 1 year postpartum. *Am J Obstet Gynecol* (2015) 213(3):367.e1–9. doi:10.1016/j.ajog.2015.05.013

66. Hromadnikova I, Kotlabova K, Hympanova L, Krofta L. Cardiovascular and cerebrovascular disease associated microRNAs are dysregulated in placental tissues affected with gestational hypertension, preeclampsia and intrauterine growth restriction. *PLoS One* (2015) 10(9):e0138383. doi:10.1371/journal.pone.0138383

67. Elton TS, Selemon H, Elton SM, Parinandi NL. Regulation of the miR155 host gene in physiological and pathological processes. *Gene* (2013) 532(1):1–12. doi:10.1016/j.gene.2012.12.009

68. Zhang Y, Diao Z, Su L, Sun H, Li R, Cui H, et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61. *Am J Obstet Gynecol* (2010) 202(5):466.e1–7. doi:10.1016/j.ajog.2010.01.057

69. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF. CYR61 (CCN1) is essential for placental development and vascular integrity. *Mol Cell Biol* (2002) 22(24):8709–20. doi:10.1128/MCB.22.24.8709-8720.2002

70. Geissmann F, Schmidt M, Dunk C, Lye SJ, Kimmig R, Winterhager E. Decreased expression of the angiogenic regulators CYR61 (CCN1) and NOV (CCN3) in human placenta is associated with pre-eclampsia. *Hum Reprod* (2006) 12(6):389–99. doi:10.1093/molehr/gal044

71. Liu Q, Yang J. Expression and significance of miR155 and vascular endothelial growth factor in placenta of rats with preeclampsia. *Int J Clin Exp Med* (2015) 8(9):15731–7.

72. Xue P, Zheng M, Diao Z, Shen L, Liu M, Gong P, et al. miR-155* mediates suppressive effect of PTEN 3'-untranslated region on AP-1/NF-kappaB pathway in HTR-8/SVneo cells. *Placenta* (2013) 34(8):650–6. doi:10.1016/j.placenta.2013.04.015

73. Dai Y, Diao Z, Sun H, Li R, Qiu Z, Hu Y. MicroRNA-155 is involved in the remodelling of human-trophoblast-derived HTR-8/SVneo cells induced by lipopolysaccharides. *Hum Reprod* (2011) 26(7):1882–91. doi:10.1093/humrep/der118

74. Cheng W, Liu T, Jiang F, Liu C, Zhao X, Gao Y, et al. microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. *Int J Mol Med* (2011) 27(3):393–9. doi:10.3892/ijmm.2011.598

75. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci U S A* (2007) 104(5):1604–9. doi:10.1073/pnas.0610731104

76. Yang X, Zhang J, Ding Y. Association of microRNA-155, interleukin 17A, and proteinuria in preeclampsia. *Medicine* (2017) 96(18):e5509. doi:10.1097/MD.0000000000006509

77. Santulli G. MicroRNAs and endothelial (Dys)function. *J Cell Physiol* (2016) 231(8):1638–44. doi:10.1002/jcp.25276

78. Salomon C, Guanzon D, Scholz-Romer K, Longo S, Correa P, Illanes SE, et al. Placental exosomes as early biomarker of preeclampsia – potential role of exosomal microRNAs across gestation. *J Clin Endocrinol Metab* (2017) 102:3182–94. doi:10.1210/jc.2017-00672

79. Jopling CL. Targeting microRNA-122 to treat hepatitis C virus infection. *Viruses* (2010) 2(7):1382–93. doi:10.3390/v2071382

80. Bouchie A. First microRNA mimic enters clinic. *Nat Biotechnol* (2013) 31(7):577. doi:10.1038/nbt.2713-577

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Bounds, Chiasson, Pan, Gupta and Chatterjee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.